Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Combined with TGA Chemotherapy for Relapsed/Refractory Yolk Sac Tumor
NCT06470464Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Countries
- 1
- Sponsor
- Shandong First Medical University
- Modality
- Small Molecules
- Drugs
- thalidomide
- Conditions
- yolk sac tumor
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in yolk sac tumor, sponsored by Shandong First Medical University. Primary endpoint: Overall Response Rate. Started Nov 2021; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Thalidomide + TGA
Thalidomide combined with nab-paclitaxel, gemcitabine, and epirubicin.
03
Who it enrols
Children <= 18 years with relapsed or refractory yolk sac tumor who have failed at least two platinum-containing regimens or recurred shortly after chemotherapy.
04
Endpoints
Primary
Overall Response Rate
Secondary
Radiographic Tumor Response Evaluation
Beyond the preview
Go deeper on NCT06470464.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470464.